Treatment of chronic hepatitis D patients with pegylated interferon: A real-world experience

Antiviral Therapy

Volumn 19, Issue 5, 2014, Pages 463-468

  Abbas, Zaigham ^a,b   Memon, Mohammad S ^c   Mithani, Hammad ^b   Jafri, Wasim ^a   Hamid, Saeed ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^b OMI Hospital   (Pakistan)

^c ISRA UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; INTERFERON; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOATING; BODY ACHE; CHRONIC HEPATITIS; CHRONIC HEPATITIS D; CLEARANCE; DECREASED APPETITE; DELTA AGENT HEPATITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; END OF TREATMENT VIROLOGICAL RESPONSE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; WEAKNESS; WEIGHT REDUCTION; DRUG EFFECTS; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON-ALPHA; INTERFERONS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84906887425     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2728     Document Type: Article

References (17)

1. Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int 2011; 31:7-21.
2. Romeo R, Del Ninno E, Rumi M, et al A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136:1629-1638.
3. Wedemeyer H. Hepatitis D revival. Liver Int 2011; 31 Suppl 1:140-144.
4. Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev 2011; 12:CD006002.
5. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19:1409-1417.
6. Erhardt A, Gerlich W, Starke C., et al Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26:805-810.
7. Castelnau C, Le Gal F, Ripault MP, et al Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44:728-735.
8. Niro GA, Ciancio A, Gaeta G.B., et al Pegylated interferon alpha-2b as mono-therapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44:713-720.
9. Wedemeyer H, Yurdaydìn C, Dalekos G.N., et al Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322-331.
10. Abbas Z, Jafri W, Raza S., Hepatitis D. Scenario in the Asia-Pacific region. World J Gastroenterol 2010; 16:554-562.
11. Seetlani NK, Abbas Z, Raza S., Yakoob J, Jafris W. Prevalence of hepatitis D in HBsAg positive patients visiting liver clinics. J Pak Med Assoc 2009; 59:434-437.
12. Mumtaz K, Hamid SS, Adil S, et al Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan. J Gastroenterol Hepatol 2005; 20:1503-1507.
13. Farci P, Mandas A, Coiana A., et al Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330:88-94.
14. Moatter T, Abbas Z, Shabir S., Jafri W. Clinical presentation and genotype of hepatitis delta in Karachi. World J Gastroenterol 2007; 13:2604-2607.
15. Abbas Z, Muzaffar R, Siddiqui A., Naqvi SA, Rizvi SA Genetic variability in the precore and core promoter regions of hepatitis B virus strains in Karachi. BMC Gastroenterol 2006; 6:20.
16. Kabaçam G., Dalekos GN, Çakaloʇlu Y, et al. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol 2012; 23:560-568.
17. Yurdaydin C, Bozkaya H, Onder F.O., et al Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008; 15:314-321.